Alder BioPharmaceuticals plans $115M stock offering

Alder BioPharmaceuticals Inc., the Bothell biotech that went public in May, is seeking to raise $115 million in a stock offering. In a Monday filing with the Securities and Exchange Commission, Alder (NASDAQ: ALDR), which is making drugs targeting migraine headaches and rheumatoid arthritis, said it will use the money for: "(1) fund our ongoing clinical program for ALD403; (2) fund the clinical development of ALD1613; (3) continue to advance and to expand our preclinical studies and potential clinical…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news